Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients
Sponsor
Janssen Research & Development, LLC (Industry)
Overall Status
Available
CT.gov ID
NCT05463939
Collaborator
(none)
3
Study Details
Study Description
Brief Summary
The purpose of this expanded access treatment protocol is to provide patients access to teclistamab prior to market authorization. The program is limited to patients with relapsed or refractory multiple myeloma who have exhausted all treatment options available as local standard of care and who are not eligible for a teclistamab clinical trial.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Study Design
Study Type:
Expanded Access
Official Title:
Teclistamab US Expanded Access Treatment Protocol for Patients With Relapsed or Refractory Multiple Myeloma
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
-
Patient diagnosed with Relapsed or Refractory Multiple Myeloma
-
Patient exhausted all commercially approved and clinically appropriate (not patient or physician preference) treatment options, and is ineligible for a clinical trial
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | DUMMY | Dummy | France | 99999 | |
2 | DUMMY | Dummy | Germany | 99999 | |
3 | DUMMY | Dummy | Italy | 99999 |
Sponsors and Collaborators
- Janssen Research & Development, LLC
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier:
NCT05463939
Other Study ID Numbers:
- CR109154
- 64007957MMY4001
First Posted:
Jul 19, 2022
Last Update Posted:
Aug 12, 2022
Last Verified:
Aug 1, 2022